Jefferies lowered the firm’s price target on Centene to $72 from $74 and keeps a Hold rating on the shares. After catching up with management, the firm views FY24 EPS of $6.80 as “possible but manufactured” and shades 16c below, adding that its 2025 EPS view is lowered by about 2% as disenrollment of healthier members is pressuring risk pools.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Centene Reaffirms Full Year Guidance, Optimistic on Medicare Performance
- Biden-Harris administration to require mental health coverage parity
- Centene price target lowered to $97 from $98 at Barclays
- Centene backs FY24 adjusted EPS view of greater than $6.80
- Centene’s Iowa Total Care awarded statewide Medicaid contract